Literature DB >> 19784396

CGRP receptor antagonists: A new frontier of anti-migraine medications.

Blanca Marquez de Prado1, Andrew F Russo.   

Abstract

Migraine is a chronic pain condition that affects 12% of the population. Currently, the most effective treatments are the triptans, but they are limited in their efficacy and have potentially deleterious cardiovascular complications. Based on basic science studies over the past decade, a new generation of anti-migraine drugs is now being developed. At the forefront of these studies is a new calcitonin gene-related peptide (CGRP) receptor antagonist that is as effective as triptans in the acute treatment of migraines, without the cardiovascular effects. This review will address the likely mechanisms and therapeutic potential of CGRP receptor antagonists.

Entities:  

Year:  2006        PMID： 19784396      PMCID： PMC2751866          DOI： 10.1016/j.ddstr.2006.11.003

Source DB:  PubMed          Journal:  Drug Discov Today Ther Strateg        ISSN： 1740-6773


  44 in total

Review 1.  The role of mast cells in migraine pathophysiology.

Authors:  Theoharis C Theoharides; Jill Donelan; Kristiana Kandere-Grzybowska; Aphrodite Konstantinidou
Journal:  Brain Res Brain Res Rev       Date:  2005-07

2.  Expression of calcitonin gene-related peptide1 receptor mRNA in human trigeminal ganglia and cerebral arteries.

Authors:  L Edvinsson; L Cantera; I Jansen-Olesen; R Uddman
Journal:  Neurosci Lett       Date:  1997-07-04       Impact factor: 3.046

3.  Calcitonin gene-related peptide: functional role in cerebrovascular regulation.

Authors:  J McCulloch; R Uddman; T A Kingman; L Edvinsson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

4.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

5.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

6.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

7.  Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs.

Authors:  J Longmore; D Shaw; D Smith; R Hopkins; G McAllister; J D Pickard; D J Sirinathsinghji; A J Butler; R G Hill
Journal:  Cephalalgia       Date:  1997-12       Impact factor: 6.292

8.  Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients.

Authors:  W H Visser; N M Jaspers; R H de Vriend; M D Ferrari
Journal:  Cephalalgia       Date:  1996-12       Impact factor: 6.292

9.  Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs.

Authors:  Kapil Kapoor; Udayasankar Arulmani; Jan P C Heiligers; Ingrid M Garrelds; Edwin W Willems; Henri Doods; Carlos M Villalón; Pramod R Saxena
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

10.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245
View more
  3 in total

1.  Analgesic Microneedle Patch for Neuropathic Pain Therapy.

Authors:  Xi Xie; Conrado Pascual; Christopher Lieu; Seajin Oh; Ji Wang; Bende Zou; Julian Xie; Zhaohui Li; James Xie; David C Yeomans; Mei X Wu; Xinmin Simon Xie
Journal:  ACS Nano       Date:  2016-12-27       Impact factor: 15.881

Review 2.  Calcitonin gene-related peptide: an update on the biology.

Authors:  Ana Recober; Andrew F Russo
Journal:  Curr Opin Neurol       Date:  2009-06       Impact factor: 5.710

Review 3.  Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications.

Authors:  Ju-Fen Yeh; Aysen Akinci; Mohammed Al Shaker; Ming Hong Chang; Andrei Danilov; Rocio Guileen; Kirk Johnson; Yong-Chul Kim; Ahmed El-Shafei; Vladimir Skljarevski; Hector Duenas; Warat Tassanawipas
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.